Vidagliptin API

Name	Vidagliptin
Chinese name	维格列汀
Cas Number	274901-16-5
Source	India
Qualifications	-/-/-/-/-

Vildagliptin is another orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitor after sitagliptin. It was approved by Swiss Novartis Pharmaceutical Co., Ltd. in September 2007 to be listed in the European Union. Vidagliptin is a representative drug of dipeptidyl peptidase inhibitors. It competitively combines with DPP-IV to form a resurrected product to inhibit its activity, thereby increasing the concentration of free GLP-1 in the plasma, exerting a hypoglycemic effect. While controlling blood sugar, it reverses the deteriorating islet function of diabetic patients. Vildagliptin is a highly selective substrate-like enzyme inhibitor that more thoroughly inhibits the enzyme activity of DPP-4, and can obtain more active GLP-1 than competitive inhibitors (such as sitagliptin) . Vildagliptin also has advantages in combination drugs, and its compound preparation with metformin is already on the market. Through large-scale clinical trials, it has been shown that the combined use of vildagliptin and metformin has a synergistic effect, enhances the efficacy, but has very low adverse reactions. Vildagliptin is a representative drug of dipeptidyl peptidase inhibitors, and the oral regular-release dosage form of vildagliptin has become the first DPP-4 inhibitor hypoglycemic agent included in the collection. Novartis's vildagliptin's global sales in 2019 were close to 1.3 billion U.S. dollars; in 2019, the terminal sales of vildagliptin in China's public medical institutions were 244 million yuan

Hot Tags: vidagliptin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Salmeterol Xinafoate API, Itraconazole Hydrochloride API, Ulipristal Acetate API, Temozolomide API, Fulvestrant API, Bivalrudine API

• Previous: Pancuronium Bromide API
• Next: Decitabine API